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In low prevalence settings, the performance of the ELF test for diagnosis of advanced fibrosis is limited and 
results in low Positive and Negative Predictive Values (PPV and NPV) using different cut-offs. In high 
thresholds and settings with high disease prevalence (>40%), the test led to high specificity (>90%) and PPV 
(>80%). However, the PPV fell significantly in primary settings with low prevalence of disease (5-10%).
Highlights
 The ELF test is measured using various algorithms that combine
the same components.
 Different predefined cut-offs are suggested in the guidelines
(and by the manufacturer) for the ELF test.
 ELF has a high sensitivity but limited specificity to exclude
NAFLD-related fibrosis.
 ELF had limited performance for diagnosing fibrosis, especially
in low-prevalence settings.
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Lay summary
The enhanced liver fibrosis test has
been suggested as a non-invasive blood
test to aid the diagnosis of severe liver
fibrosis in patients with non-alcoholic
fatty liver disease (NAFLD). Our study
results showed that the test has a high
negative predictive value, especially in
populations with low disease preva-
lence (likely encountered in primary
care); so, it can exclude advanced
fibrosis in patients with NAFLD. How-
ever, when prevalence is low, the posi-
tive predictive value of the enhanced
liver fibrosis test is low, suggesting that
additional strategies may be needed to
make a positive diagnosis in such
settings.
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Foundation Trust, Newcastle upon Tyne, UKBackground & Aims: The enhanced liver fibrosis (ELF) test has Lay summary: The enhanced liver fibrosis test has been sug-
been proposed for the non-invasive assessment of advanced
fibrosis in patients with non-alcoholic fatty liver disease
(NAFLD). We performed a systematic review to estimate the
accuracy of this test against biopsy.
Methods: In this systematic review, we searched MEDLINE,
Embase, Web of Science and the Cochrane Library for studies
that included patients with NAFLD and that used both liver bi-
opsy (as the reference standard) and the ELF test. Two authors
independently screened the references, extracted the data and
assessed the quality of included studies. Due to the variation in
reported thresholds, we used a multiple thresholds random ef-
fects model for meta-analysis (diagmeta R-package).
Results: The meta-analysis of 11 studies reporting advanced
fibrosis and 5 studies reporting significant fibrosis showed that
the ELF test had a sensitivity of >0.90 for excluding fibrosis at a
threshold of 7.7. However, as a diagnostic test at high thresholds,
the test only achieved specificity and positive predictive value
>0.80 in very high prevalence settings (>50%). To achieve a
specificity of 0.90 for advanced and significant fibrosis, thresh-
olds of 10.18 (sensitivity: 0.57) and 9.86 (sensitivity: 0.55) were
required, respectively.
Conclusion: The ELF test showed high sensitivity but limited
specificity to exclude advanced and significant fibrosis at low
cut-offs. The diagnostic performance of the test at higher
thresholds was found to be more limited in low-prevalence
settings. We conclude that clinicians should carefully consider
the likely disease prevalence in their practice setting and adopt
suitable test thresholds to achieve the desired performance.words: Non-alcoholic fatty liver disease; Fibrosis; Non-alcoholic steatohepatitis;
anced liver fibrosis test; Biomarker; Meta-analysis.
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Journal of Hepatologygested as a non-invasive blood test to aid the diagnosis of severe
liver fibrosis in patients with non-alcoholic fatty liver disease
(NAFLD). Our study results showed that the test has a high
negative predictive value, especially in populations with low
disease prevalence (likely encountered in primary care); so, it
can exclude advanced fibrosis in patients with NAFLD. However,
when prevalence is low, the positive predictive value of the
enhanced liver fibrosis test is low, suggesting that additional
strategies may be needed to make a positive diagnosis in such
settings.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Non-alcoholic fatty liver disease (NAFLD) is a potentially pro-
gressive disorder associated with the clinical features of meta-
bolic syndrome.1,2 With a global prevalence of 25%, it is now the
leading cause of chronic liver disease worldwide.3,4 NAFLD rep-
resents a wide spectrum of disease and there are a large number
of patients who can develop progressive liver fibrosis and non-
alcoholic steatohepatitis (NASH).5,6 Evidence shows that any
advance in fibrosis stage can exponentially increase liver-related
mortality.6,7 As the progression of liver fibrosis is considered the
most important predictor of NAFLD-related outcomes, early
identification of patients with NAFLD and advanced fibrosis (F3/
4) is recommended by international guidelines8–10 and is a key
area of interest for clinical trial recruitment.11
The current reference standard for diagnosis of NASH and
hepatic fibrosis is liver biopsy. However, it is invasive, resource
intensive and prone to sampling error if not of adequate size (16
Gauge needle biopsy, 20 mm length).12–14 Moreover, it carries a
small but significant risk of complications,12,14 which makes it
less suitable for diagnosis in clinical practice or in drug devel-
opment settings.
In recent years, attention has been given to non-invasive
NAFLD biomarkers. Several biomarkers have been developed2020 vol. - j 1–11
Research Article NAFLD and Alcohol-Related Liver Diseasesand studied, ranging from simple blood-based biomarkers to
more complex panels including imaging modalities. The recent
National Institute of health and Care Excellence (NICE) guideline
on NAFLD suggests the use of the enhanced liver fibrosis (ELF)
test, a non-invasive blood-derived biomarker, to aid the diag-
nosis of advanced fibrosis in the patients with NAFLD.15
The ELF test is a panel of markers that consists of 3 compo-
nents: type III procollagen peptide (PIIINP), hyaluronic acid (HA),
and tissue inhibitor of metalloproteinase-1 (TIMP1).16,17 It is
notable that, whilst the test has retained the same name, the
formula and components included have been altered sequen-
tially so not all studies reflect the performance of the currently
available test. Initially, the combination of these markers with
age was introduced as Original European Liver Fibrosis test in
2004.16 Later, the test was simplified by removing age and a new
algorithm for generating the ELF test was published in 2008.17
This algorithm was subsequently revised again by the Siemens
company and reported based on 2 different Siemens platforms.18
The clinical performance of this biomarker in NAFLD has been
reported by several studies, with variable results. The health-
economic model to support the development of the NICE
guideline reported the highest diagnostic accuracy of the ELF test
compared to 13 other diagnostic strategies. The NICE guidelines
consequently recommend that “the ELF test should be consid-
ered in people who have been diagnosed with NAFLD to test for
advanced fibrosis”, suggesting an ELF score of 10.51 as the cut-off
value.19 The estimate for the health-economic model was pro-
posed based on a single study, in a tertiary, pediatric setting.20
Most other studies used manufacturer recommended thresh-
olds for ruling advanced F3/4 fibrosis out (7.7) or in (9.8)
respectively, and reported different levels of performance of this
test.17,21–35
The variability in reported results brings into question all
recommendations regarding the ELF test as a diagnostic tool for
NAFLD-related fibrosis, with consequences for clinical diagnoses,
treatment decisions, and drug development. We aimed to
perform a systematic review and meta-analysis of the published
studies, to provide summary estimates of the accuracy of the ELF
test for diagnosing liver fibrosis and NASH in patients with
NAFLD, at the recommended thresholds, based on the currently
available evidence. In addition, we sought to evaluate alternative
cut-off values.
Materials and methods
The present study was conducted as part of a larger multi-center
project named LITMUS (Liver Investigation: Testing Marker
Utility in Steatohepatitis), which is funded by the European
Union IMI2 scheme aiming to develop, validate and qualify a
defined set of biomarkers that enable detection of NASH and
fibrosis.
Inclusion criteria
Types of studies and participants
Studies, reported in peer-reviewed journals or conference ab-
stracts, that included patients (>−18 years) with biopsy-proven or
suspected NAFLD, with paired liver histology and index
biomarker data were potentially eligible for this review. We
made no further restrictions based on either year or language.
Studies of participants with mixed etiologies were only included
if the performance of the biomarker was separately reported in
patients with NAFLD.2 Journal of HepatologyTarget condition
The target conditions were NASH (with or without fibrosis) and
staging of fibrosis (independent of NASH activity). We intended
to capture the stages of liver fibrosis using the F0 to F4 scale, as
defined by the NASH Clinical Research Network (CRN) staging
system or other scoring systems.36 Table S1 and S2 show the
different fibrosis scoring systems36–43 and various histological
scoring systems for characterizing NAFLD progression.36,44–47
Index biomarker
Using the same components, different algorithms have been
developed for ELF test, by Guha et al. 200817 and later by Siemens
(for their 2 different platforms18) to produce a score to assess
liver fibrosis:
1. Guha algorithm:
 -7.412 + 0.681 ln(HA) + 0.775 ln(PIIINP) + 0.494 ln(TIMP1)
2. Siemens algorithms:
 Using the ADVIA Centaur and ADVIA Centaur XP/XPT Systems
as an advanced automated immunoassay analyzer:
2.278 + 0.851 ln(HA) + 0.751 ln(PIIINP) + 0.394 ln(TIMP1)
 Using the ADVIA Centaur CP System as an immunoassay test
instrument for mid-volume labs:
2.494 + 0.846 ln(HA) + 0.735 ln(PIIINP) + 0.391 ln(TIMP1)
These different algorithms produce highly correlated results.
The algorithms showed a very high positive correlation (R2 =
0.995 and 0.993, respectively; Fig. S1) when compared between
2 independent studies (the first among 502 patients with biopsy-
proven NAFLD from 2 university hospitals in France; the second
among 532 patients with NAFLD from different counties), for
which we had access to the data. We therefore used the
following regression equation to harmonize the test results and
to convert all thresholds to those of the Siemens algorithm:
Siemens results = (Guha results + 8.6498)/0.8854
Reference standard
We only included studies in which histological assessment of
liver biopsy was used as the reference standard for grading and
staging of NAFLD.
Exclusion criteria
Studies were excluded if they included participants with coex-
isting liver disease (e.g. viral hepatitis), decompensated cirrhosis,
or addressed a different context of use. Letter/commentary de-
signs were also excluded. In addition, we excluded publications
that did not provide enough data to calculate diagnostic accuracy
estimates.
Search methods
The following databases were searched:
 MEDLINE via OVID
 PubMed
 Embase via OVID (including conference abstracts)
 Science Citation Index
 CENTRAL (The Cochrane Library)
A sensitive search strategy was developed in close collabo-
ration with our search specialist (RS). Table S3 shows the search
strategy for MEDLINE. The final search strategy was adapted for
different databases and initially used in August 2018. It was2020 vol. - j 1–11
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Fig 1. PRISMA flow diagram of primary studies.updated specifically for the ELF test in February 2019 and
December 2019 (Fig. 1).
To identify additional studies, we screened the reference list
of related systematic reviews and the included studies. In addi-
tion, we contacted the academic and industry partners within
the LITMUS consortium for any studies that were missed by our
search strategy.
Data collection and analysis
Selection of studies and data extraction
Using Endnote, duplicate records were removed and titles of all
records were screened by 1 reviewer (YV) while the second
reviewer screened 10% of the titles independently. Abstracts and
full texts were sought and independently assessed by 2 authors
(YV and JL). In case of any disagreement, consensus was reached
by discussion, first between 2 reviewers and if necessary, with a
senior member of the team (MHZ). The screening phase was
managed using the Rayyan software (https://rayyan.qcri.org).Journal of HepatologyThe following data were extracted by 1 author (YV/JL) and
cross checked by the other author (JL/YV): study group charac-
teristics, index test and reference test features, number of true
and false positives, and true and false negatives for constructing
classification tables.
Assessment of methodological quality
Only studies with full-text reports were assessed for methodo-
logical quality. Two authors (YV and JL) independently evaluated
the quality of included studies using the QUADAS-2 tool.48
Statistical analysis
Classification tables were extracted or reconstructed for the
performance of the index biomarker of each predefined target
condition. For the analyses, we extracted the accuracy data on
each cut-off point for which the data was available or could be
calculated.
Different studies could contribute a varying number of
thresholds, as well as different sets of thresholds. Estimates of
sensitivity, specificity, and corresponding 95% CIs were gener-
ated and graphically illustrated in forest plots.
We planned to conduct a meta-analysis whenever more than
3 studies with enough information to create classification tables
were available. We used a linear mixed effects model for
modeling the multiple thresholds data of the individual studies,
as recently proposed in “diagmeta” package in R. The multiple
thresholds model is a multilevel random effects model that en-
ables the calculation of summarized sensitivities and specificities
of different cut-off points, and the calculation of the predictive
values, given the prevalence of the target condition of
interest.49,50
Sensitivity and specificity were combined at every recom-
mended threshold and a multiple thresholds summary receiver-
operating characteristic (SROC) curve was produced. Addition-
ally, we obtained positive and negative predictive values (PPVs/
NPVs). We also calculated thresholds of the ELF test required to
achieve pre-specified (high) values of sensitivity and specificity.
We defined minimally acceptable performance levels as 0.8 for
both sensitivity and specificity, for ELF to exceed the perfor-
mance of other NAFLD-related fibrosis screening and diagnostic
biomarkers.51
The 95% CIs for sensitivity and specificity were estimated
using the delta method.50 We used a log-logistic model in our
analyses to provide estimates of the 2 cumulative distribution
functions of the test results, 1 within the disease-free and 1
within the diseased individuals, across all studies, accounting for
the between study heterogeneity and correlation between the
groups. Each data point was weighted with the inverse variance
of the respective logit-transformed proportion.
R for Windows (Version 3.6.0; R Foundation for Statistical
Computing, Vienna, Austria) was used in all analyses. For sensi-
tivity analysis, we investigated the influence of disease severity
among study groups, by removing a study with a very high
prevalence of advanced fibrosis.52 We also assessed the effect of
the test-biopsy time interval by removing studies with a long
time interval between test and liver biopsy (mean: >12
months).26,34 Heterogeneity was assessed based on visual
assessment of forest plots and ROC curves.
We did not attempt to construct funnel plots as is well known
for systematic reviews of test accuracy studies, statistical tests
based on funnel plot asymmetry cannot discriminate between2020 vol. - j 1–11 3
Research Article NAFLD and Alcohol-Related Liver Diseasespublication bias and other sources of asymmetry, like the effect
of including multiple thresholds.53
The protocol of the full systematic review is available in
PROSPERO: CRD42018106821. This study was reported using the
PRISMA-DTA statement54 (see Table S4).
Results
Search results
The initial search of the electronic databases resulted in 9,066
references. After removing duplicates, we screened 6,220 titles
and 778 abstracts. We found 265 full-text reports from the
electronic searches and 18 studies from other sources. In total,
we were able to include 17 studies that had evaluated the ac-
curacy of the ELF test in patients with NAFLD: 13 with full-text
reports17,23–30,34,35,52,55 and 4 only reported in abstracts22,31–33
(Fig. 1). Reasons for exclusion are provided in Table S5.
Study characteristics
Target population
Major characteristics of the included studies are summarized in
Table 1. The mean or median age of the participants included in
these studies ranged from 42 to 60 years. Four studies included
patients with suspected NAFLD,17,29,30,55 2 studies included
morbidly obese patients,27,35 while the remaining 11 studies
evaluated patients with biopsy-proven NAFLD. There was a
noticeable heterogeneity in severity of the disease among the
included patients in the individual studies. The prevalence of
advanced fibrosis ranged from 18% to 71%. The highest preva-
lence of advanced fibrosis was observed in a study that had
targeted enrollment of patients in the context of therapeutic
trials targeting bridging fibrosis (F3) or compensated cirrhosis
(F4) with concomitant NASH as part of 2 phase III therapeutic
clinical trials.52
Target conditions
The number of studies for each target condition is shown in
Table S7. Accuracy in detecting advanced fibrosis (F >−3) was re-
ported by 11 studies17,22–24,28–30,33,34,52,55; in detecting signifi-
cant fibrosis (F >−2) by 5
17,24,26,35,55 studies. Only 1 study reported
the performance of the test in detecting cirrhosis.52 Almost all
studies used NASH CRN (except 1 study that reported Brunt
criteria). The studies reporting on advanced fibrosis had
recruited 4,452 patients, of which 2,655 patients had fibrosis F
>−3. The studies reporting on significant fibrosis had included 550
patients with NAFLD, among whom 203 had fibrosis F >−2.
Tables S8 and S9 provide baseline characteristics of the 2 study
groups included in our meta-analyses.
ELF test algorithms and thresholds
Although the majority of the studies used the Siemens formula,
we found 3 studies that reported thresholds based on the Guha
formula.17,23,35 The thresholds reported by these studies were
converted to Siemens scale. Studies reported on different
thresholds, with a total of 8 studies reporting test accuracy at
more than 1 threshold: 7 studies included in the meta-analysis of
advanced fibrosis17,21–24,28,34 and 4 studies in significant
fibrosis.17,24,35,55
Biopsy characteristics
Not all studies provided detailed information about the biopsy.
Only 6 studies reported the length of the biopsy4 Journal of Hepatologysamples22,24,25,28,29,55; 3 studies reported the needle
gauge.24,25,28 Biopsy samples were evaluated by a single
pathologist in most of the studies; 5 studies reported evaluations
by 2 or more pathologists and only 4 studies used hep-
atopathologists. The time interval between biopsy and the blood
sampling varied significantly. Two studies reported long test-
biopsy time intervals. In 1 study the time interval between
liver biopsy and participant inclusion, when the blood samples
were collected, was up to 48 months.26 In the other study, pa-
tients with NAFLD had undergone biopsy 1.62 ± 1.75 years (mean
± SD) before blood was sampled.34 See Table S6 for details.
Methodological quality assessment
The methodological quality assessment results are summarized
in Fig. S2 and further illustrated for individual studies in Fig. S3.
Only 1 study had a low risk of bias in all 4 domains.28 Four
studies were scored high for risk of bias on the patient selection
domain, 2 on index test, and 3 on flow and timing. None of the
studies was scored as high risk of bias for the reference standard
domain. One study was considered to have concerns about
applicability, both in terms of patient selection and index test,27
since it had recruited from obese patients (14 males and 43 fe-
males), who underwent bariatric surgery in 1 hospital. The study
proposed only 1 cut-off value for diagnosing NASH with any
levels of fibrosis in obese patients with NAFLD.
As the number of studies included in the series of meta-
analyses was limited (with a maximum of 10 studies for
advanced fibrosis) sources of clinical heterogeneity were not
further explored.
Overall accuracy of ELF test for advanced fibrosis (>−F3)
Fig. S4 shows forest plots for the diagnostic accuracy of ELF test
in detecting advanced fibrosis. The studies were not consistent in
reporting the low and high thresholds. The forest plots illustrate
the heterogeneity in thresholds reported by each study and their
corresponding sensitivities and specificities.
ELF test performance in published recommended thresholds
The application of the multiple thresholds model leads to the
SROC curve (Fig. 2), which enables the estimation of sensitivities
and specificities at different thresholds, for instance for the
predefined thresholds: 7.7 and 9.8 (low and high thresholds
recommended by Siemens) and 10.51 (the high threshold rec-
ommended by NICE guideline). The area under the SROC curve
(AUC) for detecting advanced fibrosis is 0.83 (95% CI 0.71–0.90).
Table 2 shows the accuracy of the ELF test for diagnosing
advanced fibrosis at the proposed thresholds. The recommended
lower threshold of 7.7 showed a high sensitivity of 0.93 (95% CI
0.82–0.98) with a specificity of 0.34 (95% CI 0.13–0.65).
For the high thresholds, we observed a specificity of 0.86 (95%
CI 0.77–0.92) and sensitivity of 0.65 (95% CI 0.49–0.77) at ELF
>9.8 and a specificity of 0.93 (95% CI 0.85–0.96) and sensitivity of
0.51 (95% CI 0.31–0.70) at the NICE recommended threshold of
ELF >10.51.
Modeling ELF test performance for different clinical settings
and disease prevalence
In clinical practice, there is a need to understand the probability
that a NAFLD patient has or does not have advanced fibrosis
when an ELF test result exceeds a certain threshold. To address
this, we additionally used the multiple thresholds model and2020 vol. - j 1–11
Table 1. Studies included in the systematic review and meta-analysis.
Study Setting Population N M/F Mean
Age
Mean
BMI
ELF formula Target condition/N (%)
Guha 2008 Outpatients Tertiary Suspected NAFLD 192 123/69 48.7 32.4 Guha −7.412 + (ln(HA)*0.681)
+ (ln(PIIINP)*0.775) +
(ln(TIMP1)*0.494)
Advanced fibrosis (F3-4)/44 (22.9)
Significant fibrosis (F >−2)/77 (40.1)
Any fibrosis/113 (58.9)
Younossi 2011 Outpatients Hospital Obese Biopsy-proven
NAFLD
79 18/61 42.3 47.6 Guha NR Significant fibrosis (F >−2)/16 (20.3)
Any fibrosis/39 (49.4)
Dvorak 2014 Outpatients Hospital Biopsy-proven NAFLD 56 NR 45.5 30.5 Guha −7.412 + (ln(HA)*0.681) + (ln(PIIINP)*
0.775) + (ln(TIMP1)*0.494)
Advanced fibrosis (F3-4)/17 (30.3)
Karlas 2015 Outpatients Hospital Non-bariatric NAFLD 48 24/24 55.3 27.5 Siemens 2.494 + ln(CHA) + ln(CPIIINP) + ln(CTIMP−1) Significant fibrosis (F >−2)/8 (16.6)
Lykiardopoulos
2016
Outpatients Hospital Biopsy-proven NAFLD 158 117/41 60* 28.7* Siemens 2.2781 + 0.851 × ln(HA) +10.751 × l (PIIINP)
+10.934 × ln(TIMP 1)
Advanced fibrosis (F3-4)/38 (24)
Sanyal 2016 NR Biopsy-proven NAFLD 216 96/120 52.1 31.2 Siemens NR NASH with fibrosis (NAS >−4; F2-3)/95 (44)
Lopez 2017 Inpatients Hospital Bariatric 57 14/43 44.0 49.1 Siemens 2.278 + 0.851 ln(HA) + 0.751 ln(PIIINP) +
0.394 ln(TIMP-1)]
NASH or any Fibrosis/29 (50.9)
Miele 2017 Outpatients Hospital Suspected NAFLD 82 62/20 46 28.0* Siemens 2.494 + 0.846 ln(CHA) +
0.735 ln(CPIIINP) + 0.391 ln(CTIMP-1)
Advanced fibrosis (F3-4)/15 (18.3)
Boursier 2018 NR Biopsy-proven NAFLD 417 247/170 56.1 33.3 Siemens 2.278 + 0.851 ln(HA) +
0.751 ln(PIIINP) + 0.394 ln(TIMP1)
Advanced fibrosis (F3-4)/167 (40)
Eddowes 2018 Out and Inpatients
Hospital
Biopsy-proven NAFLD 54 28/26 54* 33.6 Siemens NR NASH or any Fibrosis/38 (76)
Advanced fibrosis (F3-4)/25 (50)
Significant fibrosis (F >−2)/34 (68)
Itoh 2018 Outpatients Hospital Biopsy-proven NAFLD 400 195/205 56* 27.3* Siemens 2.278 + 0.851 ln(HA) +
0.751 ln(PIIINP) + 0.394 ln(TIMP-1)]
Any fibrosis (F >−1)/334 (83.5)
Shulze 2018 NR Biopsy-proven NAFLD 74 NR NR NR NR NR Significant fibrosis (F >−2)/13 (17.6)
Staufer 2018 Outpatients Hospital Biopsy-proven NAFLD 122 NR NR NR Siemens 2.494 + 0.846 ln(HA) + 0.735 ln(PIIINP) +
0.391 ln(TIMP1)
Advanced fibrosis (F3-4)/34 (27.9)
Welsh 2018 Inpatients Hospital Biopsy-proven NAFLD 26 13/13 50 34 Siemens NR Advanced fibrosis (F3-4)/9 (34.6)
Polyzos 2019 Outpatients Hospital Suspected NAFLD 31 9/22 53.7 33 Siemens 2.278 + 0.851 × ln(HA) + 0.751 ×
ln(PIIINP) + 0.394 × ln(TIMP-1)
Advanced fibrosis (F3-4)/7 (22.6)
Anstee 2019 Outpatients Hospital Biopsy-proven NASH 3173 2010/2457 58* NR Siemens 2.278 + 0.851 ln(HA) + 0.751 ln(PIIINP) +
0.394 ln(TIMP1)
Advanced fibrosis (F3-4)/2,249 (70.9)
Cirrhosis (F4)/1,274 (40.2)
Staufer 2019 Outpatients Hospital Suspected NAFLD 181 101/80 52* 30.5* Siemens 2.278 + 0.851 ln(HA) +
0.751 ln(PIIINP) + 0.394 ln(TIMP1)
Advanced fibrosis (F3-4)/46 (25.4)
Significant fibrosis (F >−2)/68 (37.6)
NASH with advanced
fibrosis (NAS >−4; F = 3-4)/32 (17.7)
*Median. BMI, body mass index; HA, hyaluronic acid; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; NASH, non-alcoholic steatohepatitis; NR, not reported; PIIINP, type III procollagen peptide; TIMP, tissue
inhibitor of metalloproteinase-1.
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Fig. 2. Test performance for detecting advanced fibrosis. (A) Multiple
threshold ROC curves and (B) Multiple threshold SROC curve based on the
multiple thresholds model using homogenized thresholds. Circles represent
information on sensitivity and specificity. AUC: 0.83 (0.71, 0.90). Max Y-index
results: cut-off: 9.37, sensitivity: 0.73 (0.60, 0.83), specificity: 0.80 (0.68, 0.88).
AUC, area under the ROC/SROC curve; ROC, receiver-operating characteristic;
SROC, summary receiver-operating characteristic.
Research Article NAFLD and Alcohol-Related Liver Diseasescalculated the PPVs and NPVs related to the full range of
threshold values for different levels of prevalence (Fig. 2).
Employing an ELF threshold of 7.7, the highest NPV of 0.99 was
observed when using the test in a low-prevalence setting, i.e.
when the prevalence of advanced fibrosis was no more than 5%
(Table 2, Fig. 3B). We additionally reported the performance of
the ELF test for ruling out advanced fibrosis at prevalence levels
equivalent to those that may be encountered in primary and
secondary/tertiary care settings, with prevalence values ranging
between 5% to 50%, leading to NPVs between 0.99 and 0.83,
respectively.Table 2. Calculated sensitivities and specificities at predefined cut-offs of 7.7,
for different prevalences using the multiple thresholds model.
Cut-off Sensitivity 95% CI Specificity 95%
7.70 0.93 0.82–0.98 0.34 0.13–
9.80 0.65 0.49–0.77 0.86 0.77–
10.51 0.51 0.31–0.70 0.93 0.85–
11.30 0.36 0.15–0.63 0.96 0.90–
FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive pred
*Number of false positives and negatives in 100 hypothetical cases.
6 Journal of HepatologyTable 2 and Fig. 3A show the performance of the recom-
mended high-cut-off thresholds. The high threshold of 9.8 had a
mean specificity of 0.86 (95% CI 0.77–0.92), and PPV of 0.82 and
0.91 at disease prevalences of 50% and 70%, respectively.
Adopting the higher threshold of 10.51, specificity was 0.93 (95%
CI 0.85–0.96) with a PPV of 0.82 when the disease prevalence
was 40%, but the PPV fell to just 0.26 at the 5% prevalence level,
more likely to be encountered in primary care settings. An even
higher threshold of the ELF test (11.3), showed a specificity of
0.96 (95% CI 0.90–0.99), and PPV would be 0.81 in case of a
disease prevalence of at least 30%, while this fell to 0.34 at the 5%
prevalence level.
Desired thresholds for diagnosis of advanced fibrosis
Table 3 shows the desired thresholds of the ELF test for different
fixed high sensitivities (Table 3A) and specificities (Table 3B).
These results were consistent with the findings of the previous
analysis. In low cut-offs, when the prevalence was less than 50%,
the ELF test showed high sensitivities (0.90), resulting in high
NPVs, ranging from 0.82 to 0.99. However, none of the new high
thresholds showed a high PPV (>0.80) with fixed specificities
(0.90, 0.95 and 0.98) for disease prevalences of 5–20%. At the
highest threshold of 12.01, at a fixed specificity of 0.98, the ELF
test had a PPV >0.80 in settings with a prevalence of at least 30%.
Overall accuracy of ELF test for significant fibrosis (>−F2)
Five studies were included in the meta-analysis of significant
fibrosis (Fig. S5). Fig. 4 shows the SROC curve for the significant
fibrosis meta-analysis, with an AUC of 0.81 (95% CI 0.66–0.89).
The Siemens company reported that a low threshold of 7.7 per-
formed accurately in excluding significant fibrosis, when the9.8, 10.51, 11.3 in advanced fibrosis and their corresponding PPVs and NPVs
CI Prevalence PPV NPV FP* FN*
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Fig. 3. Predictive values for advanced fibrosis. (A, B) These plots illustrate the
corresponding (A) positive predictive values and (B) negative predictive values
for different ELF cut-offs based on the multiple thresholds model using all
available information for advanced fibrosis (1 color for each prevalence). ELF,
enhanced liver fibrosis.prevalence of significant fibrosis was at most 40%. In our meta-
analysis, the ELF test had a sensitivity of 0.97 (95% CI 0.88–0.99)
at this threshold, with high NPVs, ranging from 0.83 to 0.98 in
settings with disease prevalence lower than 40% (Table S10).Table 3. Calculated predictive values based on different prevalences of adv
thresholds model.
Prevalence
Fixed 0.90 sensitivity Fixe
Cut-off Specificity PPV NPV Cut-off S
0.05
0.10
0.20
0.30
0.40
0.50
0.70
8.10 0.47 0.08
0.16
0.30
0.42
0.53
0.63
0.79
0.99
0.98
0.95
0.92
0.87
0.82
0.66
7.40 0
Prevalence
Fixed 0.90 specificity Fixe
Cut-off Sensitivity PPV NPV Cut-off Se
0.05
0.10
0.20
0.30
0.40
0.50
0.70
10.18 0.57 0.23
0.39
0.59
0.71
0.79
0.85
0.93
0.98
0.95
0.89
0.83
0.76
0.68
0.47
10.95 0
NPV, negative predictive value; PPV, positive predictive value.
Journal of HepatologyHowever, the test would not be able to exclude significant fibrosis
when the prevalence was very high, as in some specialist clinical
settings, where the prevalence may exceed 40%.
None of the predefined high thresholds showed high accuracy
for diagnosis of significant fibrosis when the disease prevalence
was lower than 30%. The high threshold recommended by the
NICE guideline (10.51) would have a PPV exceeding 0.80 only in
“high-prevalence” secondary or tertiary care settings, with dis-
ease prevalence more than 40% (Table S10). At lower prevalence
levels such as 5% or 10%, as may be encountered in primary care
and non-hepatology secondary-care settings, the PPV ranged
from 0.22 to 0.66 for predefined high thresholds, while at the
highest level it reached 0.66 at a threshold of 11.30.
With pre-specified high sensitivity and specificity (0.90, 0.95
and 0.98), we could evaluate other potential ELF test thresholds
for diagnosing significant fibrosis, at different disease prevalence
values (Table S11). At a pre-specified specificity of 0.98, the
highest threshold value of 10.84 resulted in a PPV >0.80, when
the prevalence was at least 30%. The plots in Fig. 5 show the
corresponding PPVs and NPVs for different ELF thresholds at
different pretest probabilities.
Sensitivity analysis
We conducted a sensitivity analysis to examine the impact on the
meta-analytic findings of including selective patients from a pop-
ulation with very high disease prevalence. One study had selec-
tively included patients with NAFLD activity score >−3 and a
majority with bridging fibrosis (F3, 31%) or cirrhosis (F4, 40%).52
Removing this study from the meta-analysis did not significantly
affect the results of the meta-analysis. The other 2 studies that
were removed from ourmeta-analysis of advanced and significant
fibrosis had long test-biopsy time intervals (>1 year). Removing
these studies from themeta-analysis did not significantly affect the
results of the meta-analysis either26,34 (Tables S12–S17).
Discussion
Because of the limitations of the liver biopsy, non-invasive tests
to accurately evaluate fibrosis and to assess NAFLD severity are of
great interest. The ELF test has been suggested by NICE guideline
as “the most cost-effective and the most appropriate test foranced fibrosis with fixed sensitivities or specificities using the multiple
d 0.95 sensitivity Fixed 0.98 sensitivity
pecificity PPV NPV Cut-off Specificity PPV NPV
.26 0.06
0.12
0.24
0.35
0.46
0.56
0.75
0.99
0.98
0.95
0.92
0.89
0.84
0.68
6.60 0.10 0.05
0.11
0.21
0.32
0.42
0.52
0.72
0.99
0.98
0.95
0.92
0.88
0.83
0.68
d 0.95 specificity Fixed 0.98 specificity
nsitivity PPV NPV Cut-off Sensitivity PPV NPV
.42 0.31
0.48
0.68
0.78
0.85
0.89
0.95
0.97
0.94
0.87
0.79
0.71
0.62
0.41
12.01 0.25 0.40
0.58
0.76
0.84
0.89
0.93
0.97
0.96
0.92
0.84
0.75
0.66
0.57
0.36
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Fig. 4. Test performance for detecting significant fibrosis. (A) Multiple
thresholds ROC curve and (B) Multiple thresholds SROC curve based on the
multiple thresholds model using homogenized thresholds. Circles represent
information on sensitivity and specificity. AUC: 0.81 (0.66, 0.89), Max Youden-
index results: cut-off: 9.43, sensitivity: 0.69 (0.50, 0.83), specificity: 0.80 (0.60,
0.92). AUC, area under the ROC/SROC curve; ROC, receiver-operating charac-
teristic; SROC, summary receiver-operating characteristic.
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Fig. 5. Predictive values for significant fibrosis. (A, B) These plots illustrate
the corresponding (A) positive predictive values and (B) negative predictive
values for different ELF cut-offs based on the multiple thresholds model using
all available information for significant fibrosis (1 color for each prevalence).
ELF, enhanced liver fibrosis.
Research Article NAFLD and Alcohol-Related Liver Diseasesadvanced fibrosis in adults with NAFLD”.15 However, this asser-
tion was based on data extracted from a relatively small number
of clinical studies. In the present systematic review, we synthe-
sized the available evidence on the accuracy of this test by per-
forming a meta-analysis of the results of 14 studies,8 Journal of Hepatologyencompassing 4,452 and 550 patients in advanced and signifi-
cant fibrosis groups, respectively. Lack of sufficient data impeded
the conduct of a meta-analysis for other target conditions, such
as cirrhosis. The only available study of cirrhosis in 3,173 pa-
tients, reported high sensitivity of the test (83%) in excluding
cirrhosis, and high specificity in detecting cirrhosis (94%), at
thresholds of <9.8 and >−11.3, respectively.
Based on the available evidence, we can conclude that the ELF
test had a high sensitivity of 93% at the recommended low cut-
off (7.7), however specificity is limited. At the recommended
high cut-off of 9.8, specificity was 86% and even higher cut-offs
would be required to achieve higher specificity. We observed
high NPV, especially at low-prevalence settings such as in pri-
mary care, but, the PPV was much lower at this low disease
prevalence, especially when the prevalence fell below 30%.
To minimize the risk of bias due to selective inclusion of
published results, we relied on a comprehensive search strategy
for finding published full texts and conference abstracts, without
any restrictions. We also used 2 reviewers to independently
identify the studies and extract the data, to lower the risk of
errors related to single data extraction.
Because of the diversity of ELF algorithms used in the studies,
we developed a new conversion formula to harmonize the re-
sults and combine multiple algorithms used to measure this
biomarker. With our multiple thresholds model, we could use all
thresholds reported by the included studies, without limiting
ourselves to a single cut-off, as is typically done. This allowed us
to evaluate the performance of the ELF test at the predefined
thresholds, and to investigate new thresholds for predefined
levels of sensitivity and specificity that could provide predictive
values at different prevalences.
The major limitation of our systematic review and meta-
analysis was the lack of information about the biopsy proced-
ure in several individual studies. Needle gauge, the length of the
biopsy and the number of pathologists who assessed the histo-
pathological samples and their expertise were often not re-
ported. Most included studies were conducted in tertiary centers,
where the prevalence of significant and advanced fibrosis is
higher than in the general population. Therefore, limited infor-
mation about the performance of the test specifically derived
from primary clinical settings was available for this analysis.
A number of studies have evaluated the ELF test for different
purposes and in combination with other tests. However, our
systematic review is focused on diagnostic performance of the
ELF as a stand-alone test. We found 2 other systematic reviews
with the same focus. Ooi et al.56 systematically reviewed and
assessed the accuracy of a few non-invasive tests that are more
commonly used in clinical practice, including the ELF test. They
focused on the obese population, with a BMI over 30. The
prevalence of advanced fibrosis varied significantly in the
included studies, from 11% to 25.7%. In their meta-analysis they
included only 2 publications on the accuracy of the ELF test, with
significantly different thresholds (ranged from -3.37 to 0.358
based on Guha formula, equal to 5.96 to 10.17 in Siemens scale).
When comparing the results of the complex serum scores, such
as the ELF test, NAFLD fibrosis score (NFS) and Fibrosis-4 score
(FIB-4) with other single biomarkers in this study, they
concluded that the complex panels, particularly the ELF test were
more accurate.
One other related systematic review was published in 201457
and evaluated the performance of the ELF test to diagnose2020 vol. - j 1–11
different levels of fibrosis in patients with different chronic liver
conditions, including NAFLD, viral hepatitis and primary biliary
cirrhosis. Apart from the significant heterogeneity that resulted
from the wide inclusion criteria, the review suffered from a
failure to consider the variation of algorithms used to calculate
the ELF scores, the different histological scoring systems, and the
various diagnostic thresholds reported by the studies.57
Currently, there are no clear screening guidelines for NAFLD.
However, the burden for health systems on the one hand and the
risks of liver biopsy on the other, make it challenging for health
care decision makers to recommend NAFLD screening in the
community.8,9 The joint EASL-EASD-EASO guideline reviewed
the accuracy of a few serum markers including NFS, FIB-4, and
ELF test for significant and advanced fibrosis, suggesting that
“non-invasive tests may be confidently used for first-line risk
stratification to exclude severe disease”. The recent NICE guide-
line on assessment and management of NAFLD recommended
ELF as an accurate biomarker and the most cost-effective test to
detect advanced fibrosis.15
Our analysis of multiple prevalences showed that using the
ELF test at a threshold of 10.51 in primary care settings with
disease prevalence of 5–10% leads to very low PPV (0.26 and 0.43,
respectively). However, the test can lead to PPV exceeding 0.80 in
a high-prevalence setting only (>40%). Yet, at this threshold, the
summary estimate of sensitivity in detecting advanced fibrosis,
at 0.50, is well below the 1.00 mentioned in the NICE guideline.
This may question the validity of the NICE recommendation, to
“explain to people with an ELF score below 10.51 that they are
unlikely to have advanced liver fibrosis”.15
Although the available research is too limited to address
biomarker accuracy in ruling out significant and advanced
fibrosis in patients with NAFLD among the general population,
the estimations based on our study suggest that the ELF test has
a high NPV when the prevalence is lower than 30%. This high-
lights the value of the ELF test as a first-line test to exclude
advanced fibrosis in the primary care setting and hence to avoid
further evaluation by specialists. However, it is important to note
that the high sensitivity of the test (>0.90) comes at the expense
of limited specificity (0.30), which, given the low prevalence,
means there will be a substantial number of false positive results.
This needs to be considered, especially when the test is going to
be applied in a clinical setting with low prevalence of the dis-
ease, as the large number of false positive results might lead
patients to have unnecessary invasive and expensive procedures,
like biopsy.
Due to the complexity of NAFLD and the fact that it is unlikely
that a single marker would be able to accurately rule in or rule
out disease, more efforts have gone into evaluating the contri-
butions of tests.58 In 1 study, with a before-after design, the
introduction of a 2-step algorithm combining the use of FIB-4
score followed by the ELF test if required, was found to
improve the detection of advanced fibrosis and cirrhosis, while
reducing unnecessary referrals.59
ELF is now used with increasing confidence in many centers
around the world, including in the US,35 Japan,25 South Korea,60
the UK24,34 and many other European countries.26–31,33 However,
the availability of the test in clinics varies from country to
country, due to different regulatory requirements and insurance
coverage. Moreover, the test is being used in clinical settings that
differ in the prevalence of advanced fibrosis, ranging from 5–10%
in the general population to more than 30% or 40% in secondaryJournal of Hepatologyand tertiary referral centers.61 Therefore, the prevalence of
advanced fibrosis in the target population should be carefully
considered when selecting the desired test positivity threshold.
Fig. 3 and 5 in the current manuscript will assist clinicians to
identify suitable thresholds that are tailored to their specific
clinical setting/prevalence levels and the balance of sensitivity/
specificity they require.
Conclusions
The meta-analysis of the available evidence showed ELF exhibits
high sensitivity but limited specificity to exclude advanced and
significant fibrosis in patients with NAFLD, when using the low-
cut-off scores. The performance of the test for diagnosing sig-
nificant and advanced fibrosis at higher score thresholds was
also found to be limited in the context of low disease prevalence
(5–10%). These estimations were, however, projected based on
the observed cumulative distribution of the ELF in diseased and
non-diseased populations in the primary studies conducted in
higher prevalence settings. Clinicians should carefully consider
the likely a priori disease prevalence in their clinical practice
setting and select a suitable test threshold locally, to achieve the
desired level of test performance, in terms of sensitivity, speci-
ficity and predictive values. Further comparative studies of high
methodological quality are necessary to obtain more reliable
evidence of accuracy of the ELF test, especially in different clin-
ical settings.
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